STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3825 by analyst upside · 2026-08-12
LBRX
LB Pharmaceuticals Inc
Healthcare · Market Cap $1B · P/E 0x
ANALYST PRICE TARGET
+1.2%
implied upside to consensus target
Current Price $45.33
Consensus Target $45.88
Bull Target $78.0
Bear Target $36.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
1
Buy
7
Hold
0
Sell
0
52-Week Low $13.36
52-Week High $49.14
YTD Return +121.8%
FUNDAMENTALS
Market Cap $1B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-1.36
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $13.36
52-Week High $49.14
Current Price $45.33
Bear Target $36.0
Bull Target $78.0
● Now $45.33 ● Target $45.88
TRADING DATA
Avg Volume 305K
YTD Return +121.8%
Analyst Count 8
Consensus Buy
Upside to Target +1.2%
Last Updated 2026-08-12

ANALYST SUMMARY

LB Pharmaceuticals Inc (LBRX) is currently trading at $45.33 with a Wall Street consensus price target of $45.88, implying potential upside of 1.2% over the next 12 months. 8 analysts currently cover LBRX, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $78.0, while the most cautious has a target of $36.0.

LBRX operates in the Healthcare sector with a market capitalisation of $1B. The stock is up 121.8% year-to-date and is currently trading near the upper end of its 52-week range of $13.36 – $49.14.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for LBRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. ● Initiated
Buy 2026-04-27 31% win rate (48 calls)
Craig-Hallum ● Initiated
Buy 2026-04-10 Building track record
Stifel - Reiterated
Buy → Buy 2026-03-27 Building track record
Stifel - Reiterated
Buy → Buy 2025-12-11 Building track record
Stifel ● Initiated
Buy 2025-10-06 Building track record
Piper Sandler ● Initiated
Overweight 2025-10-06 14% win rate (7 calls)
Leerink Partners ● Initiated
Outperform 2025-10-06 29% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
55
out of 100
Coverage depth
17/30
Consensus clarity
11/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →